Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase

Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2026-11-18
DOI
https://doi.org/10.1126/scitranslmed.aej2067
Primary Topic
Metabolism and Genetic Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase

Cheryl K. Peck, Mercedes Barzi, Karl‐Dimiter Bissig, Timothy C. Wood et al.
4 links
Science Translational Medicine
Metabolism and Genetic Disorders
article

Rescue of glutaric aciduria type I by GalNAc-conjugated siRNA against aminoadipate semialdehyde synthase

Cheryl K. Peck, Mercedes Barzi, Karl‐Dimiter Bissig, Timothy C. Wood, Leila J. Noetzli, Ashlee R. Stiles, James Beasley, Areeg El‐Gharbawy, Beatrice Bissig-Choisat, Sarah P. Young, SABRINA BELOZEROVA, Haoyue Zhang, Maiya Fujiwara, Natasha Murugan, Yunhan Ma
article en

Abstract

Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.

Science Translational MedicineVol. 18(876)
Alnylam Pharmaceuticals (United States) (US), Duke University (US), Children's Hospital Colorado (US), Center for Human Genetics (US), Duke Medical Center (US), University of Colorado Anschutz Medical Campus (US)
Alnylam Pharmaceuticals, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, Duke Cancer Institute
Good health and well-being
Metabolism and Genetic Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon